#CHO Cell Culture Media Market
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
When “GIF” was named word of the year in 2012, Oxford Dictionaries U.S.A. credited Tumblr for pushing the word.
Text
CHO Cell Culture Media Market 2030 Has Huge Growth In Industry
CHO (Chinese Hamster Ovary) cell culture media are specifically formulated nutrient solutions used to support the growth, maintenance, and production of CHO cells in laboratory and industrial settings. CHO cells are commonly used in biopharmaceutical production for the expression of therapeutic proteins. Here is some information about CHO cell culture media:
For Download Sample Report Click Here: https://www.marketinforeports.com/Market-Reports/Request-Sample/520660
Basal Media: Basal media form the foundation of CHO cell culture media and provide essential nutrients and growth factors necessary for cell growth. They typically contain a balanced mixture of amino acids, vitamins, inorganic salts, glucose or other energy sources, and buffering agents to maintain pH stability. Basal media are usually supplemented with serum or serum substitutes, such as fetal bovine serum (FBS) or chemically defined serum-free supplements, to provide additional nutrients and growth-promoting factors.
Serum and Serum-Free Media: Traditionally, CHO cell culture media have utilized serum, such as FBS, to enhance cell growth and productivity. However, serum can introduce batch-to-batch variability and potential contamination risks. To overcome these challenges, serum-free media formulations have been developed. These media contain defined components that can support CHO cell growth and protein production without the use of animal-derived serum. Serum-free media often incorporate recombinant growth factors, hormones, and specific nutrients to mimic the growth-promoting properties of serum.
Feed Media: CHO cell cultures often require supplementation with feed media during the production phase to enhance cell viability, productivity, and protein quality. Feed media provide additional nutrients, such as amino acids, vitamins, and energy sources, to sustain the cells during the production of recombinant proteins. Feed media are typically added periodically or continuously to the culture to maintain optimal conditions for protein synthesis and prevent nutrient depletion.
Specialized Media: Depending on the specific requirements of CHO cell lines or the desired outcomes of the production process, specialized media formulations may be used. These specialized media can include chemically defined media, animal-component-free media, or media optimized for specific CHO cell lines or expression systems. These formulations are designed to provide precise control over the culture conditions and maximize protein yield and quality.
Buffer Systems: CHO cell culture media often incorporate buffering systems to maintain a stable pH within the optimal range for cell growth. Common buffer systems used include bicarbonate, phosphate, or HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). The choice of buffer system depends on the specific experimental setup and requirements.
It’s important to note that the composition and formulations of CHO cell culture media can vary among different manufacturers and laboratories. Optimization of media components and culture conditions is critical for achieving high cell viability, productivity, and protein quality in CHO cell cultures. Specific media formulations are typically tailored to the specific needs of the cell line and the intended application, and they are often developed through a combination of empirical optimization and scientific expertise.
0 notes
Text
Cell Culture Media Market worth $13.0 billion by 2028
The global cell culture media market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $13.0 billion by 2028, growing at a CAGR of 16.0% from 2023 to 2028.
Download an Illustrative overview:
Browse in-depth TOC on "Cell Culture Media Market"
359 - Tables
42 - Figures
315 – Pages
In 2022, the serum-free media segment accounted for the largest share of the type segment in the cell culture media market.
On the basis of type, the cell culture media market is divided into serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other cell culture media. In 2022, the serum-free media segment holds for the bigest share of the market. Factors responsible for the growth of this segment includes various advantages or benefits of serum-free media over other types of cell culture media.
In 2022, the biopharmaceutical production segment accounted for the largest share of the application segment in the cell culture media market.
On the basis of application, the cell culture media market is categorized into biopharmaceutical production, diagnostics, drug discovery & development, tissue engineering & regenerative medicine, and other applications. The biopharmaceutical production segment is estimated to grow at the highest growth rate during the forecast period. Factors responsible for the growth include, the growing production of cell culture-based vaccines, and expansion of pharmaceutical industry. The biopharmaceutical production applications of cell culture media include the manufacturing of biologic-based products such as vaccines, monoclonal antibodies, and other therapeutic proteins (such as anticoagulants, enzymes, blood factors, hormones, interferons, growth factors, interleukins, engineered proteins, and thrombolytics, among others).
In 2022, the Asia Pacific region is the fastest-growing region of the cell culture media market.
On the basis of the region, the global cell culture media market has been segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. During the forecast period, the Asia Pacific market is estimated to register the highest CAGR during the forecast period. Increased focus of key market players on geographical expansion in emerging markets, favorable government policies and support for cell-based vaccines in the region and less manufacturing cost are some of the major factors anticipated to have positive impact on the market growth of Asia Pacific region.
Request Sample Pages:
Key Market Players:
Key players in the cell culture media market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Corning Incorporated (US), FUJIFILM Irvine Scientific, Inc. (Japan), Lonza Group AG (Switzerland), Becton, Dickinson and Company (US), Miltenyi Biotec (Germany), and among others.
Recent Developments:
In June 2023, Thermo fisher launched Tumoroid Culture Medium to accelerate development of novel cancer therapies.
In April 2023, FUJIFILM Irvine Scientific launched BalanCD CHO Media Platform Portfolio for Bioprocessing.
In March 2022, FUJIFILM Irvine Scientific acquired Shenandoah Biotechnology. The deal would help the company to provide customers with a single point of access for their life science research, discovery, and cell and gene therapy needs.
In January 2022, Cytiva and Nucleus Biologics LLC collaborated to enhance custom cell media development for cell and gene therapies.
Cell Culture Media Market Advantages:
Versatility: Cell culture media provide a versatile platform for the growth and maintenance of various types of cells, including primary cells, stem cells, and cell lines derived from different tissues and species. This versatility allows researchers to study and manipulate diverse cell populations, facilitating a wide range of applications in basic research, drug discovery, and regenerative medicine.
Reproducibility: High-quality cell culture media formulations are standardized and extensively tested, ensuring consistent and reproducible results across different experiments and laboratories. This reliability is essential for generating meaningful and reliable data, which is critical for the advancement of scientific knowledge.
Customizability: The cell culture media market offers customizable formulations to cater to specific cell types and experimental requirements. Researchers can optimize media components to suit the unique needs of their cells, enhancing cell growth, proliferation, and differentiation, ultimately leading to more accurate and reliable experimental outcomes.
Scalability: Cell culture media have been developed to support large-scale production of cells, making them integral to biopharmaceutical manufacturing. With the increasing demand for cell-based therapies and biologics, scalable media solutions play a vital role in ensuring the efficient and cost-effective production of therapeutic cells and products.
Safety and Purity: High-quality cell culture media are manufactured under stringent quality control standards to ensure the absence of contaminants that may compromise cell viability or introduce experimental artifacts. These safety measures are essential to maintain the integrity of research findings and the safety of biopharmaceutical products.
Reduced Dependency on Animal Models: Advanced cell culture media formulations have contributed to reducing reliance on animal models in research, as they allow scientists to conduct more relevant experiments using human or cell-based models. This ethical advantage aligns with the growing focus on reducing animal testing while still advancing scientific progress.
Technological Advancements: The cell culture media market continually evolves, incorporating technological advancements, such as serum-free or xeno-free formulations, to improve cell culture systems' efficiency and reproducibility. These innovations empower researchers to work with more physiologically relevant and defined conditions, yielding results that better translate to clinical applications.
Accelerated Drug Discovery: Robust cell culture media accelerate drug discovery processes by enabling high-throughput screening of potential drug candidates on various cell models. This expedites the identification of promising compounds, shortens development timelines, and reduces drug development costs.
Overall, the cell culture media market's advantages have revolutionized modern biomedical research, playing a pivotal role in advancing scientific knowledge, drug development, and regenerative medicine, while contributing to the growth of the biotechnology and pharmaceutical industries.
#Cell Culture Media Market#Cell Culture Media Market Trends#Cell Culture Media Market Report#Cell Culture Media Industry
0 notes
Text
The Future of Autism Care: Global Cell Culture Media Market
The cell culture media market is on the cusp of remarkable growth, with projections indicating a robust Compound Annual Growth Rate (CAGR) of 6.66% over the next decade. Valued at USD 3,513.8 million in 2024, the market is expected to soar to an impressive USD 6,699.93 million by 2034.
This dynamic expansion reflects the increasing reliance on cell culture media in a variety of biotechnological and pharmaceutical applications. As the demand for advanced research and development in cell biology, drug discovery, and regenerative medicine escalates, the cell culture media market is set to experience substantial growth.
Get your PDF Sample Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-14366
The desire for personalized medication and the rising demand for biopharmaceutical goods are the main factors driving the growth of the cell culture industry. Pharmaceutical companies are extensively investing in cell culture technology to create new medications and enhance existing ones, as the prevalence of chronic diseases rises. The need for sophisticated cell culture methods has also increased as a result of the growth of tissue engineering and regenerative medicine.
The market is also expanding because to creative solutions and technological breakthroughs. To better replicate in vivo settings, scientists are always creating better culture medium, bioreactors, and 3D cell culture systems. These developments enhance cell viability, productivity, and overall efficiency, meeting the growing requirements of the biotechnology and pharmaceutical sectors.
Competitive Landscape:
Important companies like Avantor, Inc., Thermo Fisher Scientific, Inc., Caisson Laboratories Inc., Becton Dickinson and Company, Lonza Group AG, Bio-Rad Laboratories, Inc., General Electric Company, etc. are present in the worldwide cell culture media market.
Many businesses are making significant investments in R&D to develop novel and specialized formulations of cell culture medium. The aforementioned tasks involve creating specified and serum-free media, refining current formulations, and integrating cutting-edge technology to fulfill the dynamic requirements of biopharmaceutical and life sciences research.
Recent Developments
On July 12, 2023, Merck announced the expansion of its Lenexa, Kansas facility, making it the company’s largest dry powder cell culture media facility and Center of Excellence in North America.
In October 2023, London-based startup Multus Biotechnology focused on cutting the cost of cell culture media for cultivated meat by leveraging AI to optimize formulation efficiency. The startup addresses challenges in ingredient quality, scalability, and bioprocess productivity, aiming to enhance the sustainability and cost-effectiveness of cell culture media.
On July 27, 2023, MilliporeSigma invested $25 million to expand its cell culture media production facility in Lenexa, Kansas. The expansion included 98,000 ft2 of lab space, reinforcing the company’s commitment to meeting the increasing demand for cell culture media. Lenexa now serves as one of the three global centers of excellence for dry powder cell culture media manufacturing.
Key Companies in the Market:
Avantor, Inc.
Thermo Fisher Scientific, Inc.
Caisson Laboratories Inc.
Becton Dickinson and Company
Lonza Group AG
Bio-Rad Laboratories, Inc.
General Electric Company
Cell Culture Technologies LLC
Corning Incorporated
Fujifilm Holdings Corporation
Hi Media Laboratories Pvt. Ltd.
Merck & Co., Inc.
Market Segmentation:
By Type:
Serum-free Media
CHO Media
HEK 293 Media
BHK Media
VERO Cell Media
Insect Cell Media
Serum-free Stem Cell Media
CAR T-cell Media
Other Serum-free Media
Classical Media & Salts
Stem Cell Culture Media
Specialty Media
Chemically defined Media
Other Cell Culture Media
By Application:
Biopharmaceutical Production
Monoclonal antibodies
Cancer Research
Vaccines production
Other therapeutic proteins
Diagnostics
Drug Screening & Development
Tissue Engineering & Regenerative Medicine
Cell and gene therapy
Other tissue engineering & regenerative medicine applications
Other Application
By End User:
Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Laboratories
Research & Academic Institutes
Others
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East and Africa
0 notes
Text
Protein Expression Market to Witness Massive Growth Forecast to 2023-2033
Proteins, often referred to as the building blocks of life, are fundamental to nearly every biological process. From enzymes that catalyze biochemical reactions to signaling molecules that regulate cellular activities, proteins are indispensable. Protein expression is the process by which the genetic information encoded in DNA is translated into functional proteins within a cell.
The Global Protein Expression Market was valued at $2,393.0 million in 2023 and is expected to reach $6,963.6 million by 2033, growing at a CAGR of 11.27% between 2023 and 2033
Protein Expression Overview
In the pharmaceutical and biotechnology industries, protein expression is a critical component of drug discovery and development. Recombinant proteins are used as therapeutic agents themselves, such as insulin for diabetes or monoclonal antibodies for cancer treatment. Additionally, proteins are utilized in the production of vaccines, diagnostics, and biologics manufacturing processes. The ability to express proteins with high yields, purity, and biological activity is paramount for ensuring the efficacy and safety of these products.
Market Segmentation
Segmentation 1: By Application
Segmentation 2: By End User
Segmentation 3: By Product
Segmentation 4: By Expression System
Segmentation 5: By Region
Download our sample page now click here !
Applications Across the Scientific Landscape
The importance of protein expression transcends the boundaries of basic research, permeating diverse fields such as biotechnology, medicine, and industrial applications. In biopharmaceuticals, recombinant protein expression serves as the cornerstone of drug discovery and development, enabling the production of therapeutic proteins, antibodies, and vaccines.
Key Market Players
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Charles River Laboratories International, Inc.
Danaher Corporation (Abcam plc.)
GenCefe Co., Ltd.
Genscript Biotech Corporation
And many others
Recombinant Protein Expression Market
Recombinant protein expression is a testament to humanity's ingenuity in leveraging the natural machinery of cells to fulfill our scientific and commercial needs. At its core, the process involves introducing foreign DNA sequences – encoding the desired protein of interest – into host organisms such as bacteria, yeast, insect cells, or mammalian cells. Through the process of transcription and translation, these host cells become miniature protein factories, faithfully churning out the specified proteins with remarkable fidelity.
Visit our Life Sciences & Biopharma page for better understanding
Gene Expression is the process by which the information encoded within our genes is converted into functional molecules – primarily proteins and non-coding RNAs – that carry out the myriad functions of living organisms. This process unfolds in two main stages: transcription and translation. During transcription, the DNA sequence of a gene is transcribed into a complementary messenger RNA (mRNA) molecule by the enzyme RNA polymerase.
In the dynamic landscape of biotechnology, protein production technologies play a pivotal role in unlocking the potential of proteins for a myriad of applications, ranging from therapeutics and diagnostics to industrial enzymes and biopolymers.
Recent Developments in the Protein Expression Market
•In January 2024, Evosep, a leader in sample preparation for mass spectrometry-based proteomics, partnered with Thermo Fisher Scientific Inc., a global scientific leader, to advance clinical proteomics research. This collaboration would combine Evosep's sample separation technology with Thermo Fisher Scientific Inc.'s mass spectrometry instruments, enhancing proteomics research capabilities. •In July 2023, Lonza Bioscience introduced the TheraPRO CHO Media System, a novel cell culture platform designed to streamline processes and enhance productivity and protein quality, particularly when used in conjunction with GS-CHO cell lines. This release would support pharmaceutical and biotechnology companies engaged in the manufacturing of therapeutic proteins, with the goal of improving product quality and expediting time-to-market.
Key Questions Answered
Q What is the estimated global market size for the protein expression market?
Q What are the future trends expected in the protein expression market?
Q What does the supply chain and value chain of the protein expression market look like?
Q What is the regulatory framework of the protein expression market?
Q How has the COVID-19 outbreak affected the future trajectory of the protein expression market?
Q What are the market entry barriers and opportunities in the protein expression market?
Q What are the major market drivers, challenges, and opportunities of the protein expression market?
Q How is each segment of the protein expression market expected to grow during the forecast period, and what is the anticipated revenue generated by each of the segments by the end of 2033?
Q What is the growth potential of the global protein expression market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World, and what are the driving and challenging factors of the market in each of these regions?
Q Who are the leading players with significant offerings in the protein expression market, and what is the current market dominance for each of these leading players? Who are the next frontiers in the protein expression market?
Conclusion
Despite the significant advancements in protein expression technologies, several challenges persist, including the optimization of protein yields, the cost-effectiveness of production processes, and the scalability of manufacturing operations. Additionally, the complexity of mammalian expression systems poses challenges in terms of cell line development, process optimization, and regulatory compliance.
#Protein Expression Market#Recombinant Protein Expression Market#Gene Expression Analysis Market#Protein Production Technologies
0 notes
Text
Serum-Free Media (SFM) Market Overview on Rising Demands and Supply 2021 to 2026: Thermo Fisher Scientific, Cyagen Biosciences, Biomimetics Sympathies
The global research report titled “Serum-Free Media (SFM) Market” has recently been published by The Research Insights which helps to provide guidelines for the businesses. It has been aggregated based on different key pillars of businesses such as drivers, restraints, and global opportunities. This Serum-Free Media (SFM) Market research report has been compiled by using primary and secondary research techniques. Finally, researchers direct their focus on some significant points to give a gist about investment, profit margin, and revenue.
(Get Impressive Discount)
Download a Sample Copy of This Report(including full TOC, Tables and Figures):
https://www.theresearchinsights.com/request_sample.php?id=370890&mode=Arundhati
The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Serum-Free Media (SFM) Market: Thermo Fisher Scientific, Cyagen Biosciences, Biomimetics Sympathies, Cambrex, Nobimpex, Biological Industries, Sigma-Aldrich, Lonza, Irvine Scientific, Thermo Fisher Scientific
This report segments the global Serum-Free Media (SFM) Market based on Types are:
Chinese Hamster Ovary (CHO) Cell Media
Insect Media
Hybridoma Media
Vaccine Production Media
Based on Application, the Global Serum-Free Media (SFM) Market is segmented into:
Nutritional Supplements
Recombinant Protein Production
Insect Cell Culture
Buy Exclusive Report @:
https://www.theresearchinsights.com/checkout?id=370890&mode=Arundhati
Regional analysis of Global Serum-Free Media (SFM) Market:
Geographically, the global Serum-Free Media (SFM) Market has been fragmented into several regions such as North America, Latin America, Asia-Pacific, Africa, and Europe based on the productivity of several companies. Every segment along with its sub-segments is analyzed in the research report. The competitive landscape of the market has been elaborated by studying numerous factors such as top manufacturers, prices, and revenue.
The information on the global Serum-Free Media (SFM) Market is accessible to readers in a logical chapter-wise format. Driving and restraining factors have been listed in this research report, which helps to understand positive and negative aspects in front of the businesses.
Access Full Report information with TOC, here:
https://www.theresearchinsights.com/reports/COVID19-Global–China-SerumFree-Media-SFM-Market-Research-by-Company-Type–Application-20152026-370890?mode=Arundhati
What are the market factors that are explained in the report?
-Key Strategic Developments: The Serum-Free Media (SFM) Market study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.
-Key Market Features: The Serum-Free Media (SFM) Market report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.
-Analytical Tools: The Global Serum-Free Media (SFM) Market report includes the accurately studied and assessed data of the key industry players and their scope in the market using several analytical tools. The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the key players’ growth in the market.
Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.
About us:
The Research Insights – A global leader in analytics, research, and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations, and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.
Contact us:
Robin
Sales manager
Contact number: +91-996-067-0000
https://www.theresearchinsights.com
0 notes
Text
Lab-grown meat could be on store shelves by 2022, thanks to Future Meat Technologies
Are consumers ready for meat grown in a lab?
Companies like Memphis Meats, Aleph Farms, Higher Steaks, Mosa Meat and Meatable are all trying to bring to supermarkets around the world meat made from cultivated animal cells, but the problem has always been the cost.
Now, Future Meat Technologies has raised $14 million in new financing to build its first pilot manufacturing facilities to bring the cost of production of a cell-made steak down to $10 per pound — or $4 if the meat is combined with plant-based meat substitutes.
The $10 price tag is a whole lot lower than the $50 target that experts from the Good Food Institute were talking about back in April of this year — and represents a significant cost reduction that makes lab-grown meat a potentially commercially viable option much sooner than anyone expected.
“With this investment, we’re thrilled to bring cultured meat from the lab to the factory floor and begin working with our industrial partners to bring our product to market,” said Rom Kshuk, the chief executive officer of Future Meat Technologies, in a statement. “We’re not only developing a global network of investors and advisors with expertise across the meat and ingredient supply chains, but also providing the company with sufficient runway to achieve commercially viable production costs within the next two years.”
Unlike its other competitors, Future Meat Technologies doesn’t have any interest in selling its products directly to consumers. Rather, the company wants to be the supplier of the hardware and cell lines that anyone would need to become a manufacturer of lab-grown meat.
In a way, it’s not much different to the approach that Tyson Foods — an investor in Future Meat through its venture capital arm — has taken with farmers. Tyson contracts with poultry farmers to raise the chickens that the company slaughters and processes, and provides them with the means to raise the chickens for slaughter.
Future Meat production tanks for meat and fat
The secret to Future Meat’s success is its use of undifferentiated fibroblast cells that can be triggered with small molecules to turn into either fat cells or muscle cells. Once the fat and muscle starts growing, they’re placed in a culture with a specific resin that removes waste materials that have been an impediment to growth at large scales, according to chief science officer and founder Yaakov Nahmias.
While Future Meat doesn’t rely on fetal bovine serum to grow its meat products, it does use small molecules derived from CHO cells (Chinese hamster ovaries), which are used in new medical research and drug manufacturing.
“We have a specific resin to remove the toxins from the media and that allows the cells to continue to grow,” says Nahmias. “It is essentially a new bioreactor design… you can increase the yield to 80%.. For every liter of medium you don’t get 100 grams of biomass you can get 800 grams of biomass… [and] you don’t talk about mega $100 million factories.”
Nahmias says using a refrigerator-sized bioreactor, a manufacturer could get about half a ton of meat and fat in about 14 days. In about one month, growers can make an amount of meat equivalent of two cows’ worth of meat (a cow takes about 12 to 18 months to raise for slaughter).
The former Hebrew University of Jerusalem professor first began thinking about the lab-grown meat business while on sabbatical. “It was at a Peet’s Coffee right next to the Charles River in Cambridge,” Nahmias recalled. “Somebody asked me what I thought about cultured meat… They asked me what I thought about it and I told them it was the stupidest idea I had ever heard in my entire life.”
Growing cells is expensive, Nahmias said at the time, and the fact that the organisms basically grow in their own excrement means that they can’t reproduce effectively to reach any kind of large scale. That’s when Nahmias had his “Eureka” moment. “You need cells that grow without any growth factor at all,” says Nahmias. “The only cells that can do that are the least differentiated cells, which are fibroblasts.”
With the new financing from investors — including S2G Ventures, a Chicago-based venture firm (and an early investor in Beyond Meat); Emerald Technology Ventures, a Swiss investment firm; Tyson Ventures (one of the most active strategic investors); and Bits x Bites (a Chinese investor in food and agriculture startups) — Future Meat can now test its business model and manufacturing capabilities at scale.
Future Meat leadership, Dr. Moria Shimoni, EVP of R&D; Yaakov Nahmias, CTO and founder; and Rom Kshuk, CEO
“You’re either growing fat or you’re growing muscle of a specific species,” says Nahmias. “Imagine a large truck going to that facility. [It’s] replacing the meat packing plant. From there the biomass goes through a process like extrusion. You can have thousands of these mass producing units. [It’s] going to a central facility where the meat comes out at the end. What we are doing is looking for parity and cost.”
For Nahmias, the fat’s the thing that brings the flavor for everything. “The fat gives you the aroma and the distinct flavor of meat,” says Nahmias. “This is the missing ingredient in Impossible Foods and Beyond Meat .”
Nahmias envisions products that are made using a combination of Future Meat’s lab-grown products and plant proteins that can approximate the full flavors of beef, chicken or lamb (all meats that the company says it is working with).
All Nahmias wants is for Future Meat to get to market; the founder doesn’t care whether that’s under Tyson’s brand or anyone else’s. “I want to be the largest company you’ve never heard of,” says Nahmias. “I want to make a product that is more sustainable and more cost-efficient, and is better for everybody.”
Like all of the other companies pursuing alternatives to animal husbandry, Future Meat, which was only founded last year, has a mission to reduce the environmental impact of meat eating. The company argues that its manufacturing model will reduce land use by 99% and emit 80% less greenhouse gas than traditional meat production.
“This continues our investment in Future Meat Technologies, which is focused on disruptive technologies related to our core business,” said Amy Tu, president of Tyson Ventures, in a statement. “We are broadening our exposure to alternative ways of producing protein to feed a growing world population.”
Ultimately the goal is getting to cost parity with regular beef. The company thinks a hybrid product could be $3 to $4, while the 100% biomass product would be roughly $10.
“We’re taking a yes and ‘Yes and’ as opposed to an either-or approach to the space,” says Matthew Walker, a managing director at S2G Ventures. “You will have animal-based meat, plant-based meat and you will have hybrid products. It’s more about the supply chain and the technological products that would bring this product to market. We think there’s room in the market for somebody to play that role.”
Nahmias and Kshuk think that’s the role Future Meat Technologies was born to play.
0 notes
Text
Hyundai Motors restyles leftover materials into fashion statements
Hyundai collaboration with renowned NYC-based fashion brand Zero + Maria Cornejo to present 15 piece fashion collection utilising leftover Hyundai car seat materials
Hyundai Motor Company is partnering with ready-to-wear fashion brand Zero + Maria Cornejo to host Re:Style, an exclusive cultural event showcasing a creative upcycling collaboration between the automotive and fashion industries.
The event will take place on September 6, the opening night of the 2020 S/S New York Fashion Week, at the trendy Public Kitchen restaurant in New York.
Re:Style focuses on upcycling, an emerging cultural trend that encourages the transformation of leftover materials into new products.
The event will present a vision for the creative reuse of automotive materials for fashion and connect with people who care deeply about the environment and seek more ethical consumption.
The event’s theme, “saving the planet in style,” will bring to life a collaboration between Hyundai Motor Company, Hyundai Transys (a Hyundai parts company and one of the premier car seat manufacturers in the world) and New York based-fashion brand Zero + Maria Cornejo.
For the project, the automotive brand and Zero + Maria Cornejo have produced a 15 piece capsule collection reusing the leftover leather produced after the seat development by Hyundai Transys and upcycled Zero + Maria Cornejo fabrics, including a 100 percent organic cotton Cradle to Cradle Certified Gold Dylan denim, reimagined in entirely new shapes and silhouettes.
The original collection will be presented at the Re:Style event.
“The whole idea is to do something creative with things that have had a life before,” said Maria Cornejo. “It is about making something new and re-imagining things. Re-create, re-imagine, re-cycle. How do we get creative with less?”
Zero + Maria Cornejo is recognised as an eco-friendly designer brand known for using natural dyes, natural silk, and materials that require minimal oil, and is also renowned for taking the conservation of natural ecosystems and environmental issues into consideration.
Zero + Maria Cornejo is famous for being worn by numerous celebrities and luminaries.
“Our brand designed Re:Style to further our mission of becoming a more sustainable company and to create dialogue around eco-conscious lifestyles,” said Wonhong Cho, Global Chief Marketing Officer of Hyundai Motor Company.
“This cultural event in the heart of New York City allows us to partner with one of the preeminent eco-friendly designers and share our vision for progressing humanity.
“We are aiming to prove that you can create something beautiful and new from something that was once used.”
A large number of influential domestic and foreign celebrities, including fashion influencers, designers, stylists, and media will attend Re:Style, along with famous socialites and influencers who support sustainable activity.
Hyundai and Zero + Maria Cornejo have also designed a run of limited edition T-shirts that will be sold in-store and on Zero + Maria Cornejo’s website, with the proceeds benefiting environmental organisations.
The programme will also include branded content and a partnership with Nylon, a leading pop culture and fashion media outlet.
Re:Style is the second cultural project from Hyundai following the successful “StyleNite” event in Los Angeles late last year and is a part of the brand’s creative approach to reach young and trend-focused millennials by teaming up with key figures in the fashion industry.
The collaboration is also another step towards Hyundai making an impact in sustainability and lessening its eco-footprint, as evidenced by the recent debut of the Hyundai NEXO, its first dedicated fuel cell electric vehicle that produces zero carbon emissions.
The company has also worked with the BBC on a series titled “Innovators of Tomorrow” which shares innovators’ vision for a better future as well as sponsoring various global initiatives including a Sustainable Water Circulation Project in the Philippines and a Dream Village Project improving the underdeveloped villages in Chennai, India.
The article Hyundai Motors restyles leftover materials into fashion statements appeared first on World Branding Forum.
0 notes
Text
Cell Culture Media for Vaccine Market - Size, Share, Outlook, and Opportunity Analysis
Global Cell Culture Media for Vaccine Market – A Novel Approach in Disease Management
Cell culture media for vaccine plays a major role in advanced healthcare, as it regulates the cell cycle. It is the growth medium, available in liquid or gel form, developed to support growth of microorganisms, cells, or small plants.
The global cell culture media for vaccine market size was valued at US$1,235.5million in 2018, and is expected to exhibit a CAGR of 7.7 % over the forecast period (2018 – 2026)
Request A Sample Copy: http://bit.ly/2z9xwvE
Increasing prevalence of infectious diseases is expected to propel growth of the global cell culture media for vaccine market
High prevalence of infectious diseases is expected to drive the market growth over the forecast period. According to the Centers for Disease Control and Prevention (CDC), in 2017, around 9,105 tuberculosis cases and around 42,743 cases of lyme disease were reported in the U.S. Also, according to the study conducted by University of Oxford, 2018, the measles cases are currently high in several European countries, where over 82,500 measles cases were registered in Europe in 2018. The number was thrice as compared in 2017, while 15 times in comparison with 2016.
Moreover, increasing availability of innovative bovine blood plasma derivatives is expected to augment the market growth. For instance, in April 2015, Rocky Mountain Biologicals, Inc., a life science and bioprocessing company, launched high-performance Fetal Bovine Serum alternative — Fetalgro. Fetalgro is a proprietary blend of a calf serum base and proprietary additive that matches the Fetal Bovine Serum’s (FBS) cell growth capabilities in CHO, MRC-5, Vero, and a wide range of other cell lines.
Increasing investments by government organizations and manufacturers focusing on promoting immunization in North America is expected to bolster the market growth
The increasing investments by government organizations and manufacturers focusing on promoting immunization is expected to drive the cell culture media for vaccine market. For instance, in 2015, the Centers for Medicare & Medicaid Services (CMS), with the Centers for Disease Control and Prevention (CDC) introduced a five-year initiative, Healthy People 2020 to improve immunization as well as to reduce the disparity rates caused majorly due to pneumonia, shingles, and influenza. The organizations worked directly with physicians and provider offices, home health agencies, hospitals, and beneficiaries under the guidance of Health Service Advisory Group (HSAG) to promote their initiative.
Moreover, increasing number of vaccine clinical trial in the North America is expected to augment the market growth. For instance, in April, 2018, BiondVax Pharmaceuticals Ltd. enrolled participants in the U.S. for a Phase 2 clinical trial of the company’s universal flu vaccine candidate, M-001.
Key Players
Major players operating in the global cell culture media for vaccine market include HiMedia Laboratories, Thermo Fisher Scientific Inc., Merck KGaA, General Electric Company, Sartorius AG, Proliant, Inc., Bovogen Biologicals Pty. Ltd., Rocky Mountain Biologicals, Valley Biomedical, Moregate BioTech, Atlanta Biologicals, Creative-Biolabs, Life Technologies (India) Pvt Ltd., Axil Scientific Pte Ltd., Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Sisco Research Laboratories Pvt. Ltd., and Valneva SE
Click To Read More On Cell Culture Media for Vaccine Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Bridging the Gap: How the Global Cell Culture Media Market is Expanding Access to Care
The global cell culture media market is expected to have steady growth and, by 2034, be valued at an estimated US$6,699.93 million. From a market value of US$3,513.8 million in 2024, this amounts to a Compound Annual Growth Rate (CAGR) of 6.66% during the forecast period.
In the life sciences sector, the cell culture market is expanding quickly and is essential to many types of research, medication development, and biotechnology applications. The practice of cultivating and preserving cells outside of their natural habitat in a controlled environment is known as cell culture. These cultured cells are an invaluable resource for scientists and researchers because they offer important insights into disease causes, cell behavior, and treatment responses.
Preview Next-Level Insights Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-14366
The desire for personalized medication and the rising demand for biopharmaceutical goods are the main factors driving the growth of the cell culture industry. Pharmaceutical companies are extensively investing in cell culture technology to create new medications and enhance existing ones, as the prevalence of chronic diseases rises. The need for sophisticated cell culture methods has also increased as a result of the growth of tissue engineering and regenerative medicine.
The market is also expanding because to creative solutions and technological breakthroughs. To better replicate in vivo settings, scientists are always creating better culture medium, bioreactors, and 3D cell culture systems. These developments enhance cell viability, productivity, and overall efficiency, meeting the growing requirements of the biotechnology and pharmaceutical sectors.
Competitive Landscape:
Important companies like Avantor, Inc., Thermo Fisher Scientific, Inc., Caisson Laboratories Inc., Becton Dickinson and Company, Lonza Group AG, Bio-Rad Laboratories, Inc., General Electric Company, etc. are present in the worldwide cell culture media market.
Many businesses are making significant investments in R&D to develop novel and specialized formulations of cell culture medium. The aforementioned tasks involve creating specified and serum-free media, refining current formulations, and integrating cutting-edge technology to fulfill the dynamic requirements of biopharmaceutical and life sciences research.
Recent Developments
On July 12, 2023, Merck announced the expansion of its Lenexa, Kansas facility, making it the company’s largest dry powder cell culture media facility and Center of Excellence in North America.
In October 2023, London-based startup Multus Biotechnology focused on cutting the cost of cell culture media for cultivated meat by leveraging AI to optimize formulation efficiency. The startup addresses challenges in ingredient quality, scalability, and bioprocess productivity, aiming to enhance the sustainability and cost-effectiveness of cell culture media.
On July 27, 2023, MilliporeSigma invested $25 million to expand its cell culture media production facility in Lenexa, Kansas. The expansion included 98,000 ft2 of lab space, reinforcing the company’s commitment to meeting the increasing demand for cell culture media. Lenexa now serves as one of the three global centers of excellence for dry powder cell culture media manufacturing.
Key Companies in the Market:
Avantor, Inc.
Thermo Fisher Scientific, Inc.
Caisson Laboratories Inc.
Becton Dickinson and Company
Lonza Group AG
Bio-Rad Laboratories, Inc.
General Electric Company
Cell Culture Technologies LLC
Corning Incorporated
Fujifilm Holdings Corporation
Hi Media Laboratories Pvt. Ltd.
Merck & Co., Inc.
Market Segmentation:
By Type:
Serum-free Media
CHO Media
HEK 293 Media
BHK Media
VERO Cell Media
Insect Cell Media
Serum-free Stem Cell Media
CAR T-cell Media
Other Serum-free Media
Classical Media & Salts
Stem Cell Culture Media
Specialty Media
Chemically defined Media
Other Cell Culture Media
By Application:
Biopharmaceutical Production
Monoclonal antibodies
Cancer Research
Vaccines production
Other therapeutic proteins
Diagnostics
Drug Screening & Development
Tissue Engineering & Regenerative Medicine
Cell and gene therapy
Other tissue engineering & regenerative medicine applications
Other Application
By End User:
Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Laboratories
Research & Academic Institutes
Others
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East and Africa
0 notes
Text
Cell Line Development Market Set for Rapid Growth | Trend and Analysis, 2018-2026
Development of novel therapy to drive growth of the cell line development market
Cell line development has wide application areas. Development of immunotherapy for the treatment of cancer is major application of cell line development. According to the World Health Organization factsheet 2012, cancer is one of the leading cause of death from top three causes of non-communicable disease. Pharmaceutical and biotechnological companies are focusing on developing novel therapies such as immunotherapy due to its specificity and efficiency. Cell line development helps in speeding drug discovery process and optimization of clinical trials by providing high yield of monoclonal antibodies, which is expected to fuel growth of the cell line development market.
Browse Full Report: https://www.coherentmarketinsights.com/ongoing-insight/cell-line-development-market-1286
Increasing technological advancements in cell line development are expected to boost growth of the cell line development market. For instance, in November 2017, Lonza group launched Multiplex Cell line culture using GS Xceed Gene Expression System., which helps in testing multiple drug candidate at early developmental stage thereby saving four to six months, which otherwise is required in conventional development program.
North America to dominate the market for cell line development due to high investment in research by pharmaceutical companies to develop novel product
North America is expected to hold the dominant position in the global cell line development market, owing to high investment by pharmaceutical companies in developing a novel treatment product and increasing off patenting of major products, which would promote biosimilar drug development. Biosimilar drug having biological molecule needs to match in structure and composition with original product which needs cell line to confirm matching of structure and adhere to quality attribute such as glycoprofile, protein aggregation. For instance, according to 2016 report of International Trade Administration of Department of Commerce (USA), the U.S. generic drug sales reached an estimated US$ 70 billion in 2015, which represents quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favoring generics development. According to the same report, biologics account for over a third of all new drugs in clinical trials or which are waiting for FDA approval. According to Pharmaceutical Research and Manufacturers of America, companies such as Novartis AG, Merck and Company and F. Hoffmann-LA Roche AG in U.S. together invested in US$ 75 billion in research and development. Legal factors such Affordable Care Act which has already covered most of population would boost the usage for novel products as patients can get treated with insurance coverage without out of pocket expenditure on such medication.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1286
Collaborations by cell line development companies with drug discovery companies to speed up expansion of cell line development market
Some of the major players operating in the global cell line development market include Lonza Group AG, Sigma-Aldrich Corporation, Wuxi App Tec, Inc., American Type Culture Collection, Thermo Fisher Scientific, Inc., PX’Therapeutics SA., Selexis SA, GE Healthcare, European Collection of Cell Cultures , Corning, Inc., Sartorious AG, Goodwin Biotechnology Inc., and Cleancells. These companies are entering into strategic partnership with drug discovery companies to optimize their product development:
In December 2017, Selexis SA and Turgut Pharmaceuticals announced to enter into a third commercial license agreement, which would provide Turgut with access to Selexis SUREtechnology Platform and SURE CHO-M Cell Line for the development of biosimilar product for the treatment of two rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The companies were already in agreement (made in July 2016) to develop biosimilar products to treat inflammatory diseases and certain cancers using the SURE CHO-M Cell Lines.
Request TOC of the Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1286
Cell Line Development Market Taxonomy
On the basis of Product type: Reagents & Media, Equipment, On the basis of source: Mammalian, Non-Mammalian,. On the basis of cell line: Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line,.On the basis of application: Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research,. On the basis of end user: Pharmaceutical companies, Research and Academic Institution,.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
Visit our news Website: https://www.coherenttimes.org
0 notes
Text
Serum-Free Media (SFM) Market Development Trends and Qualitative Analysis 2020
Latest Global Serum-Free Media (SFM) Market research report is an in-depth study of the industry including basic structures. This report features market revenue, share, development and market size. Also accentuate Serum-Free Media (SFM) industry contribution, product picture and provision. It examines a competitive summary of worldwide market forecast between period 2020 to 2025.
The Global Serum-Free Media (SFM) market report gives information covering market competition, creation, revenue, export, import, supply, utilization, market overview, market examination by applications and market impact factors analysis. These reports are resulting with market intelligence, economy and value. The report offers operational advisory and business intelligence on ‘Serum-Free Media (SFM) Market’, emphasizing on emerging business models, problematic advancements alongside point of reference investigation and achievement contextual analyses. It additionally covers the demand-supply gap, difficulties and specialty sections in the ecosystem
Get Free Sample Copy for more Professional and Technical insights at: https://www.globalinforeports.com/request-sample/1081567
Leading Players are:
Nobimpex, Thermo Fisher Scientific, Cambrex, Irvine Scientific, Biomimetics Sympathies, Lonza, Cyagen Biosciences, Biological Industries, Thermo Fisher Scientific, Sigma-Aldrich
The Serum-Free Media (SFM) report uttered an entire view of this market by substituting it when it comes to application as well as region. Trends examines regional segmentation integrates prospective and present requirement for them from the North America, Europe, Asia Pacific, South America, Middle East & Africa. The report covers the major applications of industry in the leading region.
Major Types are:
Vaccine Production Media
Insect Media
Hybridoma Media
Chinese Hamster Ovary (CHO) Cell Media
Major Applications are:
Insect Cell Culture
Recombinant Protein Production
Nutritional Supplements
Avail Discount on Report @ https://www.globalinforeports.com/check-discount/1081567
This Report will address some of the most important questions which are listed below:
Which is the main local/country for the development of the market? What is the anticipated growth rate of the leading regions during the forecast period?
What is the market size of the Serum-Free Media (SFM) market at the worldwide level?
Which mode of distribution channel is most preferred by the manufacturers of Serum-Free Media (SFM)?
What the key factors driving, inhibiting the growth of the market and what is the degree of impact of the drivers and restraints?
What is the impact of the regulations on the growth of the Serum-Free Media (SFM) market?
How are the emerging markets for Serum-Free Media (SFM) expected to act in the coming years?
Who are the major players working in the global Serum-Free Media (SFM) market? What is the present market position of the key players? Who are the rising players in this industry?
The Serum-Free Media (SFM) report stipulates economic scenarios with all the thing value, the principal area, benefits, distributions, limitations, creation, petition, market enhancement, and figure and so forth. The Serum-Free Media (SFM) report introduces speculation attainability evaluation, a task SWOT investigation, and venture yield evaluation.
Have Any Query? Ask Our Industry Experts @ https://www.globalinforeports.com/send-an-enquiry/1081567
Customization of this Report: This Serum-Free Media (SFM) report could be customized to the customer's requirements. Please contact our sales professional ([email protected]), we will ensure you obtain the report which works for your needs.
0 notes
Text
Hyundai Motors restyles leftover materials into fashion statements
Hyundai collaboration with renowned NYC-based fashion brand Zero + Maria Cornejo to present 15 piece fashion collection utilising leftover Hyundai car seat materials
Hyundai Motor Company is partnering with ready-to-wear fashion brand Zero + Maria Cornejo to host Re:Style, an exclusive cultural event showcasing a creative upcycling collaboration between the automotive and fashion industries.
The event will take place on September 6, the opening night of the 2020 S/S New York Fashion Week, at the trendy Public Kitchen restaurant in New York.
Re:Style focuses on upcycling, an emerging cultural trend that encourages the transformation of leftover materials into new products.
The event will present a vision for the creative reuse of automotive materials for fashion and connect with people who care deeply about the environment and seek more ethical consumption.
The event’s theme, “saving the planet in style,” will bring to life a collaboration between Hyundai Motor Company, Hyundai Transys (a Hyundai parts company and one of the premier car seat manufacturers in the world) and New York based-fashion brand Zero + Maria Cornejo.
For the project, the automotive brand and Zero + Maria Cornejo have produced a 15 piece capsule collection reusing the leftover leather produced after the seat development by Hyundai Transys and upcycled Zero + Maria Cornejo fabrics, including a 100 percent organic cotton Cradle to Cradle Certified Gold Dylan denim, reimagined in entirely new shapes and silhouettes.
The original collection will be presented at the Re:Style event.
“The whole idea is to do something creative with things that have had a life before,” said Maria Cornejo. “It is about making something new and re-imagining things. Re-create, re-imagine, re-cycle. How do we get creative with less?”
Zero + Maria Cornejo is recognised as an eco-friendly designer brand known for using natural dyes, natural silk, and materials that require minimal oil, and is also renowned for taking the conservation of natural ecosystems and environmental issues into consideration.
Zero + Maria Cornejo is famous for being worn by numerous celebrities and luminaries.
“Our brand designed Re:Style to further our mission of becoming a more sustainable company and to create dialogue around eco-conscious lifestyles,” said Wonhong Cho, Global Chief Marketing Officer of Hyundai Motor Company.
“This cultural event in the heart of New York City allows us to partner with one of the preeminent eco-friendly designers and share our vision for progressing humanity.
“We are aiming to prove that you can create something beautiful and new from something that was once used.”
A large number of influential domestic and foreign celebrities, including fashion influencers, designers, stylists, and media will attend Re:Style, along with famous socialites and influencers who support sustainable activity.
Hyundai and Zero + Maria Cornejo have also designed a run of limited edition T-shirts that will be sold in-store and on Zero + Maria Cornejo’s website, with the proceeds benefiting environmental organisations.
The programme will also include branded content and a partnership with Nylon, a leading pop culture and fashion media outlet.
Re:Style is the second cultural project from Hyundai following the successful “StyleNite” event in Los Angeles late last year and is a part of the brand’s creative approach to reach young and trend-focused millennials by teaming up with key figures in the fashion industry.
The collaboration is also another step towards Hyundai making an impact in sustainability and lessening its eco-footprint, as evidenced by the recent debut of the Hyundai NEXO, its first dedicated fuel cell electric vehicle that produces zero carbon emissions.
The company has also worked with the BBC on a series titled “Innovators of Tomorrow” which shares innovators’ vision for a better future as well as sponsoring various global initiatives including a Sustainable Water Circulation Project in the Philippines and a Dream Village Project improving the underdeveloped villages in Chennai, India.
The article Hyundai Motors restyles leftover materials into fashion statements appeared first on World Branding Forum.
from WordPress https://glenmenlow.wordpress.com/2019/08/28/hyundai-motors-restyles-leftover-materials-into-fashion-statements/ via IFTTT
0 notes
Text
Hyundai Motors restyles leftover materials into fashion statements
Hyundai collaboration with renowned NYC-based fashion brand Zero + Maria Cornejo to present 15 piece fashion collection utilising leftover Hyundai car seat materials
Hyundai Motor Company is partnering with ready-to-wear fashion brand Zero + Maria Cornejo to host Re:Style, an exclusive cultural event showcasing a creative upcycling collaboration between the automotive and fashion industries.
The event will take place on September 6, the opening night of the 2020 S/S New York Fashion Week, at the trendy Public Kitchen restaurant in New York.
Re:Style focuses on upcycling, an emerging cultural trend that encourages the transformation of leftover materials into new products.
The event will present a vision for the creative reuse of automotive materials for fashion and connect with people who care deeply about the environment and seek more ethical consumption.
The event’s theme, “saving the planet in style,” will bring to life a collaboration between Hyundai Motor Company, Hyundai Transys (a Hyundai parts company and one of the premier car seat manufacturers in the world) and New York based-fashion brand Zero + Maria Cornejo.
For the project, the automotive brand and Zero + Maria Cornejo have produced a 15 piece capsule collection reusing the leftover leather produced after the seat development by Hyundai Transys and upcycled Zero + Maria Cornejo fabrics, including a 100 percent organic cotton Cradle to Cradle Certified Gold Dylan denim, reimagined in entirely new shapes and silhouettes.
The original collection will be presented at the Re:Style event.
“The whole idea is to do something creative with things that have had a life before,” said Maria Cornejo. “It is about making something new and re-imagining things. Re-create, re-imagine, re-cycle. How do we get creative with less?”
Zero + Maria Cornejo is recognised as an eco-friendly designer brand known for using natural dyes, natural silk, and materials that require minimal oil, and is also renowned for taking the conservation of natural ecosystems and environmental issues into consideration.
Zero + Maria Cornejo is famous for being worn by numerous celebrities and luminaries.
“Our brand designed Re:Style to further our mission of becoming a more sustainable company and to create dialogue around eco-conscious lifestyles,” said Wonhong Cho, Global Chief Marketing Officer of Hyundai Motor Company.
“This cultural event in the heart of New York City allows us to partner with one of the preeminent eco-friendly designers and share our vision for progressing humanity.
“We are aiming to prove that you can create something beautiful and new from something that was once used.”
A large number of influential domestic and foreign celebrities, including fashion influencers, designers, stylists, and media will attend Re:Style, along with famous socialites and influencers who support sustainable activity.
Hyundai and Zero + Maria Cornejo have also designed a run of limited edition T-shirts that will be sold in-store and on Zero + Maria Cornejo’s website, with the proceeds benefiting environmental organisations.
The programme will also include branded content and a partnership with Nylon, a leading pop culture and fashion media outlet.
Re:Style is the second cultural project from Hyundai following the successful “StyleNite” event in Los Angeles late last year and is a part of the brand’s creative approach to reach young and trend-focused millennials by teaming up with key figures in the fashion industry.
The collaboration is also another step towards Hyundai making an impact in sustainability and lessening its eco-footprint, as evidenced by the recent debut of the Hyundai NEXO, its first dedicated fuel cell electric vehicle that produces zero carbon emissions.
The company has also worked with the BBC on a series titled “Innovators of Tomorrow” which shares innovators’ vision for a better future as well as sponsoring various global initiatives including a Sustainable Water Circulation Project in the Philippines and a Dream Village Project improving the underdeveloped villages in Chennai, India.
The article Hyundai Motors restyles leftover materials into fashion statements appeared first on World Branding Forum.
0 notes
Text
Cell Culture Media for Vaccine Market Overview, SWOT Analysis And 2025 Forecast
Cell culture media for vaccine plays a major role in advanced healthcare, as it regulates the cell cycle. It is the growth medium, available in liquid or gel form, developed to support growth of microorganisms, cells, or small plants.
The global cell culture media for vaccine market size was valued at US$ 1,235.5 million in 2018, and is expected to exhibit a CAGR of 7.7 % over the forecast period (2018 – 2026)
High prevalence of infectious diseases is expected to drive the market growth over the forecast period. According to the Centers for Disease Control and Prevention (CDC), in 2017, around 9,105 tuberculosis cases and around 42,743 cases of lyme disease were reported in the U.S. Also, according to the study conducted by University of Oxford, 2018, the measles cases are currently high in several European countries, where over 82,500 measles cases were registered in Europe in 2018. The number was thrice as compared in 2017, while 15 times in comparison with 2016. Moreover, increasing availability of innovative bovine blood plasma derivatives is expected to augment the market growth. For instance, in April 2015, Rocky Mountain Biologicals, Inc., a life science and bioprocessing company, launched high-performance Fetal Bovine Serum alternative — Fetalgro. Fetalgro is a proprietary blend of a calf serum base and proprietary additive that matches the Fetal Bovine Serum’s (FBS) cell growth capabilities in CHO, MRC-5, Vero, and a wide range of other cell lines.
However, high risk of contamination is expected to hinder the market growth. The use of serum in vaccine production leads to problems such as the components of bovine serum being carried into the vaccine as a contaminant from the cell culture medium.
Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/2608
The increasing investments by government organizations and manufacturers focusing on promoting immunization is expected to drive the cell culture media for vaccine market. For instance, in 2015, the Centers for Medicare & Medicaid Services (CMS), with the Centers for Disease Control and Prevention (CDC) introduced a five-year initiative, Healthy People 2020 to improve immunization as well as to reduce the disparity rates caused majorly due to pneumonia, shingles, and influenza. The organizations worked directly with physicians and provider offices, home health agencies, hospitals, and beneficiaries under the guidance of Health Service Advisory Group (HSAG) to promote their initiative.
Moreover, increasing number of vaccine clinical trial in the North America is expected to augment the market growth. For instance, in April, 2018, BiondVax Pharmaceuticals Ltd. enrolled participants in the U.S. for a Phase 2 clinical trial of the company’s universal flu vaccine candidate, M-001.
Key Players
Major players operating in the global cell culture media for vaccine market include HiMedia Laboratories, Thermo Fisher Scientific Inc., Merck KGaA, General Electric Company, Sartorius AG, Proliant, Inc., Bovogen Biologicals Pty. Ltd., Rocky Mountain Biologicals, Valley Biomedical, Moregate BioTech, Atlanta Biologicals, Creative-Biolabs, Life Technologies (India) Pvt Ltd., Axil Scientific Pte Ltd., Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Sisco Research Laboratories Pvt. Ltd., and Valneva SE
Increasing prevalence of infectious diseases is a major factor driving the global cell culture media for vaccine market growth. According to the Centers for Disease Control and Prevention (CDC), in August 2017, around 104 laboratory-confirmed influenza-associated pediatric deaths were reported, where 66 cases were associated with influenza A viruses and 38 cases were associated with influenza B viruses in the U.S. Moreover, the government initiatives for increasing awareness among the populace regarding prevention of diseases facilitated by vaccines is expected to boost the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden in the U.S.
However, high risk of contamination may hinder the market growth. According to the article published in ResearchGate, 2014, fetal bovine serum (FBS) is known to contain factors such as endotoxins, mycoplasma, viral contaminants, and prions that can lead to bovine spongiform encephalopathy (BSE).
Click To Reading More On Cell Culture Media for Vaccine Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Global Market Study on Serum-Free Media – Growth, Drivers, Opportunities, Limitations, Manufacturers, Regions & Key Players to 2026
Global Serum-free media Market’ for the period 2018–2026”. The primary objective of the report is to offer updates and information related to market opportunities in the global serum-free media market.
The Global Serum-free media Market is Segmented Based on:
Media Type End User Region This report covers the global serum-free media market performance in terms of revenue contribution from various segments. The report begins with an overview and market definitions. The market viewpoint section underlines the macro-economic factors influencing the growth of the global serum-free media market along with detailing the opportunity analysis of the market. This is then followed by the key drivers, restraints and trends of the global serum-free media market.
By media type, the global serum-free media market is segmented into protein expression media, stem cell media, hybridoma media, primary cell media, insect cell media, immunology media, Chinese hamster cell (CHO) culture media and chemically defined media. The CHO cell culture media is expected to be the dominant segment in the global serum-free media market due to wide use in therapeutic protein production. The CHO cell culture media in serum-free media is high in North America and Europe due to high number of biopharmaceutical companies in the region. Whereas, chemically defined media in serum-free media remains least lucrative segment.
To Get Free Sample Copy of Report Visit: https://www.researchmoz.us/enquiry.php?type=S&repid=1935281
By end users, the global serum-free media market is segmented into biopharmaceutical companies, clinical research organizations and academic research centers.
By region, the global serum-free media market has been segmented into North America (the U.S. & Canada), Latin America (Brazil, Mexico, and Rest of Latin America), Europe (Germany, France, the U.K., Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand and Rest of Asia Pacific), and Middle East and Africa (GCC Countries, South Africa, Israel and Rest of MEA).
A detailed analysis has been provided for each region in terms of serum-free media market size, Y-o-Y growth rate, absolute $ opportunity, and attractive index. The forecast of the serum-free media market by country, media type and end user is represented in a tabular form. This section will help to understand the present scenario and opportunity of the serum-free media market in major countries by each segment.
Read Overview of Report @ https://www.researchmoz.us/global-market-study-on-serum-free-media-chinese-hamster-ovary-cell-culture-to-remain-dominant-media-type-through-2026-report.html
In the next section of the report, the “Competitive Landscape” is included to provide report audiences with a dashboard view of the key competitor firms in order to access the key differentiators among the competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to a segment. The detailed profiles of players operating in the serum-free media market are also provided in the report, which highlight company description, product/segment overview, SWOT analysis, financial information, key developments related to the serum-free media market and the strategic overview.
The next section of the report highlights the serum-free media market outlook for 2018–2026 and sets the forecast within the context of the serum-free media market by region.
The above sections – by media type and end user – evaluate the historic market analysis and growth prospects of the serum-free media market for the period 2018–2026. We have considered 2017 as the base year and provided data for the forecast period.
The final section of the report represents the global scenario of the serum-free media market along with y-o-y growth and market forecast till 2026. This section also evaluates the global serum-free media market opportunity over the forecast period as well as the absolute dollar opportunity for each year. This section will help to understand the overall market growth for serum-free media and the opportunity analysis for every year over the forecast period.
Make An Enquiry@ https://www.researchmoz.us/enquiry.php?type=E&repid=1935281
To arrive at the serum-free media market size, bottom-up approach is used to validate the total market size obtained for the serum-free media market. The forecast presented in the report provides total revenue of the serum-free media market over 2018–2026. PMR uses the triangulation methodology, which is primarily based on experimental techniques such as patient-level data to obtain precise market estimations for the serum-free media market and insights on specific country/regions. The country-specific data is again analyzed to derive data at a regional level and then at a global level. This methodology ensures high quality and accuracy of information.
The factors considered while developing the estimates of the serum-free media market are epidemiology, treatment seeking rate, ratio of population prescribed with different serum-free media.
On the other hand PMR has also analyzed the serum-free media market by considering the revenue from the key players operating in the market. The key players are segmented at a Tier-level with respect to their revenues, product portfolio and geographical presence. This process involves analysis of annual reports of various companies, investor presentations, SEC filings, 10k reports, earning call transcripts and press releases. This task is done to fetch substantial information about the key players, their respective revenues and estimate their respective market share.
The revenue growth of the key players in serum-free media market is analyzed over the historical period and qualitative assessment of new product launches and innovations has been made in order to validate and align the resultant serum-free media market numbers. The market structure is closely studied and analyzed at a regional level to map and ascertain incremental $ opportunity for companies, for instance, supply from domestic/regional players, small-scale enterprises or unorganized segments is also taken into consideration to arrive at the final market numbers.
While forecasting the market size for the serum-free media market, we have considered the impact of several factors such as per capital healthcare expenditure, disposable income, new serum-free media products and approvals for new advanced serum-free media products, penetration of serum-free media products to various end users across all regions, among others. However, quantifying the serum-free media market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the serum-free media market and to identify the right growth opportunities in the global serum-free media market.
About ResearchMoz ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact: ResearchMoz Mr. Nachiket Ghumare, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Website: https://www.researchmoz.us Email: [email protected] Blog: https://researchknowledgeresource.blogspot.com/ Follow us on LinkedIn @ http://bit.ly/1TBmnVG
0 notes
Text
Cell Freezing Media Market : Estimated to Experience a Hike in Growth by 2024
The global cell freezing media market is foreseen to gain momentum in its growth due to biopharmaceutical and pharmaceutical industries receiving government help for research through several impactful initiatives. Besides drug development, there are other types of programs that largely benefit from cell freezing on the part of storage. A report by Transparency Market Research (TMR) gives sound knowledge about how the market could grow in the coming years and projects its growth on the basis of revenue and CAGR. It bears the title “Cell Freezing Media Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
Read Report Overview: https://www.transparencymarketresearch.com/cell-freezing-media-market.html
However, one of the factors that could arrest the world cell freezing media market is expensive maintenance cost when it comes to storage. Nonetheless, the report gives out critical information on a number of trends and opportunities anticipated to help lift up the market in the presence of certain challenges. On the basis of end user, the market could see segmentation into academics and research, pharmaceutical firms, and biopharmaceutical firms.
Taking into account the rate at which research activities are growing, biopharmaceutical firms are expected to exhibit faster growth in the world cell freezing media market. On the other hand, the market could find growth in the pharmaceutical industry due to increasing application of cell freezing media in the formation of regenerative medicine and drug screening of various kinds of medicines.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20492
The world cell freezing media market could also be classified as per media type. Here, the segments could be vaccine production media, insect media, hybridoma media, and Chinese hamster ovary (CHO) cell media. Vaccine production media could be further segregated into fetal bovine serum (FBS), cell line media, additional vaccine media, classic media and salts, and other animal sera. Considering the significant breakthrough it has brought about in the healthcare industry, it could be said that insect media may grow at a handsome rate in the market. Genetically engineered cell lines can be developed by insect media to help express recombinant proteins that are therapeutically valuable.
On the other hand, monoclonal antibodies in cell culture system can be developed by hybridoma media. CHO cells could have great potential in bioprocessing and pharmaceutical research as well. They could harvest different types of recombinant glycoproteins on a large scale. Regionally, the international cell freezing media market is foretold to testify the rise of Europe and North America as larger geographies. Markets in these regions could gain impetus due to new drug development backed by rising number of research and development activities. With countries such as India, China, and Japan, Asia Pacific could be a more progressive market for cell freezing media.
Request For TOC: https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=20492
Some of the leading players of the international cell freezing media market are Nippon Genetics, Thermo Fisher Scientific, Inc., and Merck KGaA.
About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/
0 notes